Cover Image
市場調查報告書

眼科藥物輸送:市場概要、輸送技術、聯盟的機會

Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities

出版商 MCD Group, LLC 商品編碼 524306
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
眼科藥物輸送:市場概要、輸送技術、聯盟的機會 Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities
出版日期: 2017年07月05日 內容資訊: 英文 144 Pages
簡介

提供本報告提供眼科藥物輸送市場全面的概要,詳細的產品、技術信息,市場資料,各治療分類的DDS (藥物遞輸系統) 開發平台,企業簡介,及聯盟的機會等相關分析。

簡介

第1章 眼科疾病

  • 老年性黃斑部病變 (AMD)
  • 黃斑部水腫及糖尿病視網膜病變
  • 青光眼
  • 發炎性疾病

第2章 市場概要

  • 主要企業

第3章 眼科藥物輸送形勢

  • 非侵襲輸送技術
  • 侵襲輸送技術
  • 已經過核准眼內DDS (藥物遞輸系統) 產品
  • 眼內DDS開發平台
  • 開發機會
  • 未來展望

第4章 技術簡介

  • 新的氣霧劑 & 點眼藥設備
    • CIS Pharma
    • Eyenovia, Inc.
    • Mystic Pharmaceuticals, Inc.
    • Nemera
    • SpinDrift Therapeutics
  • 淚管塞
    • Mati Therapeutics, Inc.
    • Ocular Therapeutix., Inc.
  • 局部輸送技術
    • Aciont, Inc.
    • Amorphex Therapeutics, Inc.
    • Apidel SA
    • EyeCRO, LLC
    • EyeGate Pharma
    • EyeTrans Technologies, Inc.
    • InSite Vision, Inc.
    • Integral Ophthalmics, LLC
    • Kala Pharmaceuticals, Inc.
    • Nanomerics
    • Novaliq GmbH
    • Oculis Pharma
    • Santen SAS
    • Seagull Technologies Pty Ltd
  • 注射、植入
    • AsclepiX Therapeutics, LLC
    • Clearside Biomedical, Inc.
    • DelSiTech, Ltd
    • Envisia Therapeutics, Inc.
    • Glaukos Corporation
    • Graybug Vision, Inc.
    • Icon Bioscience, Inc.
    • iVeena Delivery Systems
    • KMG Pharma, LLC
    • Layer Bio, Inc.
    • Midatech Pharma, PlC
    • Neurotech Pharmaceuticals, Inc.
    • Ocuject, LLC
    • Ohr Pharmaceutical, Inc.
    • Peregrine Ophthalmic Pte Ltd
    • PolyActiva Pty Ltd
    • pSivida Corporation
    • Replenish, Inc.
    • Spinnaker Biosciences, Inc.
    • Taiwan Liposome Company Limited
    • TheraKine, Ltd
  • 眼植入
    • Allergan plc
    • ViSci Ltd. Visual Sciences
  • 藥物釋放型晶體
    • Leo Lens Technology, Inc.
    • OcuMedic, Inc.

圖表

目錄

Summary

It is an exciting time in the field of ocular drug delivery, with a number of innovative delivery systems showing promise. The market is currently dominated by topical products such as drops and ointments which are inefficient and can be difficult to administer properly. Injectable formulations are available to a lesser extent and can be associated with serious side effects and require administration by a medical professional. Fortunately there are a record number of companies developing improved ocular delivery systems which provide benefits such as sustained release, accurate dosing, and ease of administration. These companies range from emerging start-ups with preclinical projects to established specialty companies with late-stage pipeline products. Collectively, these companies have more than 70 novel ocular formulations and products in various stages of development for indications such as glaucoma, uveitis, macular degeneration, and dry eye disease.

This 144 page report provides a comprehensive overview of the ocular drug delivery segment and includes detailed product and technology information, market data, DDS pipelines by therapeutic category, company profiles, and partnering opportunities.

Report Contents

  • Eye Diseases
  • Overview and prevalence data
  • Marketed therapeutics by indication
    • Age-related macular degeneration
    • Macular edema
    • Diabetic retinopathy
    • Glaucoma
  • Ophthalmic Market Overview
  • Sales of top ten ophthalmic products, 2015-2016
  • Key players by revenue
  • Key players with drug delivery-enabled products
  • Ocular Drug Delivery Landscape
  • Non-invasive and invasive delivery technologies
  • Approved ocular drug delivery formulations
  • Ocular drug delivery pipeline by therapeutic category
  • Future perspectives and development opportunities
  • 46 Company Profiles by Technology Type
  • Novel aerosol and eye drop devices
  • Punctal plugs
  • Topical delivery systems
  • Injectables and implants
  • Ocular inserts
  • Drug-eluting lenses

For each company profiled, the following information is provided:

  • Technology Description
  • Development Status / Pipeline Products
  • Patents and Publications
  • Partnership Opportunities
  • Business Development & Licensing Contact

Sample of Companies Profiled:

AciontEnvisia Therapeutics
EyeGate PharmaGraybug Vision
iVeenaKala Pharmaceuticals
KMG PharmaLeo Lens Technology
Mati TherapeuticsOcular Therapeutix
Oculis PharmapSivida
Spindrift TherapeuticsViSci, Ltd.

Reasons to Buy:

  • Identify enabling delivery systems or devices for pipeline drugs
  • Scout technologies for life cycle management of commercialized ophthalmic drugs
  • Understand the key players and therapeutic segments
  • Obtain product and technology information for launched ophthalmics
  • View pipeline details for novel ocular formulations in development
  • Discover product and technology licensing opportunities

Table of Contents

Introduction

Chapter I: Eye Diseases

  • Age Related Macular Degeneration (AMD)
  • Macular Edema and Diabetic Retinopathy
  • Glaucoma
  • Inflammatory Conditions

Chapter II: Market Overview

  • Key Players

Chapter III: Ophthalmic Drug Delivery Landscape

  • Non-Invasive Delivery Technologies
  • Invasive Delivery Technologies
  • Approved Ocular DDS Products
  • Ocular DDS Pipeline
  • Development Opportunities
  • Future Perspectives

Chapter IV: Technology Profiles

  • Novel Aerosol & Eye Drop Devices
    • CIS Pharma
    • Eyenovia, Inc.
    • Mystic Pharmaceuticals, Inc.
    • Nemera
    • SpinDrift Therapeutics
  • Punctal Plugs
    • Mati Therapeutics, Inc.
    • Ocular Therapeutix., Inc.
  • Topical Delivery Technologies
    • Aciont, Inc.
    • Amorphex Therapeutics, Inc.
    • Apidel SA
    • EyeCRO, LLC
    • EyeGate Pharma
    • EyeTrans Technologies, Inc.
    • InSite Vision, Inc.
    • Integral Ophthalmics, LLC
    • Kala Pharmaceuticals, Inc.
    • Nanomerics
    • Novaliq GmbH
    • Oculis Pharma
    • Santen SAS
    • Seagull Technologies Pty Ltd
  • Injectables & Implants
    • AsclepiX Therapeutics, LLC
    • Clearside Biomedical, Inc.
    • DelSiTech, Ltd
    • Envisia Therapeutics, Inc.
    • Glaukos Corporation
    • Graybug Vision, Inc.
    • Icon Bioscience, Inc.
    • iVeena Delivery Systems
    • KMG Pharma, LLC
    • Layer Bio, Inc.
    • Midatech Pharma, PlC
    • Neurotech Pharmaceuticals, Inc.
    • Ocuject, LLC
    • Ohr Pharmaceutical, Inc.
    • Peregrine Ophthalmic Pte Ltd
    • PolyActiva Pty Ltd
    • pSivida Corporation
    • Replenish, Inc.
    • Spinnaker Biosciences, Inc.
    • Taiwan Liposome Company Limited
    • TheraKine, Ltd
  • Ocular Inserts
    • Allergan plc
    • ViSci Ltd. Visual Sciences
  • Drug Eluting Lenses
    • Leo Lens Technology, Inc.
    • OcuMedic, Inc.

Tables & Figures

  • Table 1: Eye Disease Prevalence
  • Table 2: Wet AMD Therapeutics
  • Table 3: Injectable Steroids for Macular Edema
  • Table 4: Topical Glaucoma Products
  • Table 5: Ocular Anti-Inflammatory Products
  • Figure 1: Ophthalmic Products by Administration Route
  • Table 6: Top-selling Prescription Ophthalmic Products 2015-2016
  • Table 7: Ophthalmic Revenues of Key Players
  • Table 8: Key Players with Ocular DDS Products
  • Table 9: Comparison of Non-Invasive Ocular DDS
  • Table 10: Comparison of Invasive Ocular DDS
  • Figure 2: Timeline for Sustained Release Ocular Implant Products
  • Table 11: Approved Ophthalmic Drug Delivery Products
  • Table 12: Topical Glaucoma DDS Pipeline
  • Table 13: Sustained Release Glaucoma Pipeline
  • Table 14: Uveitis and Macular Edema DDS Pipeline
  • Table 15: Ocular Pain and Inflammation DDS Pipeline
  • Table 16: Macular Degeneration DDS Pipeline
  • Table 17: Dry Eye DDS Pipeline
  • Table 18: Ocular Pipeline Products with Drug Delivery Technology Needs
  • Table 19: Eyenovia Pipeline
  • Table 20: Mati Therapeutics Pipeline
  • Table 21: Ocular Therapeutix Pipeline
  • Table 22: Aciont Pipeline
  • Table 23: Amorphex Pipeline
  • Table 24: EyeGate Pipeline
  • Table 25: InSite Vision Pipeline
  • Table 26: Kala Pipeline
  • Table 27: Novaliq Pipeline
  • Table 28: Oculis Pipeline
  • Table 29: Santen Pipeline
  • Table 30: Advantages of AsclepiX Peptide Formulations vs Competitors
  • Table 31: Clearside Bio Pipeline
  • Table 32: Envisia Pipeline
  • Table 33: Highlights of Graybug GB-102
  • Table 34: Graybug Vision Pipeline
  • Table 35: Icon Bioscience Pipeline
  • Table 36: iVeena Pipeline
  • Table 37: KMG Intravitreal and Subconjunctival Microneedle Injectors
  • Table 38: KMG Intravitreal and Subconjunctival Needleless Injectors
  • Table 39: KMG Submucosal Needleless Injectors
  • Table 40: KMG Semi-Automated and Manual Intravitreal Injectors
  • Table 41: Neurotech Pipeline
  • Table 42: Leo Lens Technology Advantages
Back to Top